Recent progress concerning CpG DNA and its use as a vaccine adjuvant.

Abstract

CpG Oligonucleotides (ODN) are immunomodulatory synthetic oligonucleotides designed to specifically agonize Toll-like receptor 9. Here, we review recent progress in understanding the mechanism of action of CpG ODN and provide an overview of human clinical trial results using CpG ODN to improve the vaccines for cancer, allergy and infectious disease.

• Authors: Hidekazu Shirota, Dennis M Klinman
• Journal: Expert review of vaccines (Expert Rev Vaccines) Vol. 13 Issue 2 Pg. 299-312 (Feb 2014) ISSN: 1744-8395 [Electronic] England
• PMID: 24308579 (Publication Type: Journal Article, Research Support, N.I.H., Intramural, Review)

Chemical References

• Adjuvants, Immunologic
• CPG-oligonucleotide
• Oligodeoxyribonucleotides
• Toll-Like Receptor 9
• Vaccines

Topics

• Adjuvants, Immunologic (administration & dosage)
• Clinical Trials as Topic
• Humans
• Oligodeoxyribonucleotides (administration & dosage)
• Toll-Like Receptor 9 (drug effects, immunology)
• Vaccines (administration & dosage, immunology)